This is the Direct plan of Nippon India Nifty Pharma ETF — bought from the fund house, with no distributor commission in its expense ratio. Income is retained in the fund, so it shows up as NAV rather than as a payout.
Performance
Scorecard
Not ratedHow this is computed
Each verdict is computed from this fund's own metrics against its sub-category — the number behind it is shown, not a black-box rating. Not rated — too few comparable ETF funds (same plan and option) to rank against yet.
3Y CAGR +19.93% · ranks 2 of 20 Other ETFs funds
Volatility 15.1% vs 16.0% category avg
0.2% expense vs 0.3% category avg
100% of rolling 3Y windows were positive
Strengths & concerns
Generated from this fund's own numbers against its sub-category — each point names the figure behind it.
Strengths
- Ahead of the Other ETFs average on 1M/3M/6M/1Y — 1Y by 20.54pp
- 3-year return (+19.93%) beats the Other ETFs average (+11.37%)
- 5-year return (+13.09%) beats the Other ETFs average (+9.22%)
- Ranks #3 of 33 on 1-year return in its Other ETFs cohort
- Stronger risk-adjusted returns — Sharpe 0.89 vs 0.21 Other ETFs average
Concerns
No significant concerns identified.
Key Metrics
Scheme Info
DefinitionsPeriod returns (<1Y, absolute — not annualized)
DefinitionsAnnualized returns (≥1Y — CAGR)
DefinitionsAdvanced metrics — risk and benchmark ratios
Fund vs category average (Other ETFs)
| Period | Fund | Category avg. | Diff |
|---|---|---|---|
| 1M abs | -1.81% | -5.28% | +3.47% |
| 3M abs | +4.67% | -3.22% | +7.89% |
| 6M abs | +19.80% | +2.06% | +17.74% |
| 1Y CAGR | +21.50% | +0.96% | +20.54% |
| 3Y CAGR | +19.93% | +11.37% | +8.56% |
| 5Y CAGR | +13.09% | +9.22% | +3.87% |
Category average across peers in Other ETFs (up to 35 funds with data), same plan and option, excluding this fund. Under-1-year figures are absolute; 1Y and beyond are annualised (CAGR).
Not sure what a figure means? The glossary explains every metric, and the methodology shows the formulas.
Category rank
Vs 35 peers in Other ETFs
Backtest this fund
What a SIP or one-time investment would have grown to over this fund’s real NAV history.
60 monthly installments of ₹10,000 into Nippon India Nifty Pharma ETF, valued at the latest NAV. XIRR annualizes for each installment’s timing.
Calendar-year returns
What the fund actually returned in each year, not the smoothed average.
| Year | Fund | Nifty 500 TRI | Diff | |
|---|---|---|---|---|
| 2026part | +16.24% | -7.18% | +23.42% | |
| 2025 | -2.46% | +7.94% | -10.40% | |
| 2024 | +39.59% | +16.43% | +23.16% | |
| 2023 | +34.44% | +27.43% | +7.01% | |
| 2022 | -10.86% | +4.34% | -15.20% | |
| 2021part | -1.02% | — | — |
January–December, from this fund's NAV history. Absolute return, not annualised. “part” marks a year the fund didn't run end to end — its first year, the current year so far, or one it stopped reporting in; those years show no benchmark comparison.
Taxation
Taxed as equityThis is an equity-oriented fund (≥65% in Indian equities), so gains get the concessional capital-gains rates below — they do not add to your income-tax slab.
Flat, on the whole gain
On gains above ₹1.25 L per financial year
Applies to capital gains on redemption. Excludes IDCW/dividend tax, STT, surcharge and cess, and pre-2018 equity grandfathering. For research only — consult a tax advisor before filing.
Asset allocation
As on 31 Aug 2026 · AMC disclosure- Equity99.95%
- Cash & Equivalents0.05%
Fund size over time
Quarterly average AUM · AMFIAt or near its largest, ₹1,458Cr in April - June 2026. Size matters most where the mandate is narrow — a large small-cap or a very large flexi-cap book is harder to move without moving the price.
Net flow is an estimate: AMFI publishes a quarterly average AUM, not a closing balance, and it covers every plan and option of this scheme together, so it is a read on direction and rough size rather than a cash-flow statement.
AMC Profile
Nippon India Mutual Fund is managed by Nippon Life India Asset Management, which took control of the former Reliance Mutual Fund in 2019 when Nippon Life of Japan bought out the Reliance Capital stake. It is among India's largest fund houses by assets and is best known for its small- and mid-cap franchise.
Fund Managers
JTJitendra TolaniManaging since 01 Feb 2025
Fund manager & Dealer – Passives
MBA (Finance)
Over 18 years of experience From June 10, 2024 onwards NAM India - Designated as Fund Manager & Dealer Passives February 2016 - May 2024 Motilal Oswal Financial Services Ltd: Designated as VP Sales Trading, Institutional Equities – BeES, Nippon India ETF Nifty Dividend Opportunities 50 and responsible for handling trades 500 Low Volatility 50 Index Fund, and Nippon India Nifty 500 for domestic institutions August 2013 – February 2016 Asit C Mehta Investment Interrmediaries Ltd: Designated as DVP Sales Trading, Institutional Equities- responsible for handling the dealing team & also to handle trades for domestic institutions
- CPSE ETF
- Nippon India ETF Nifty 50 Shariah BeES
- Nippon India ETF Nifty 50 Value 20
- Nippon India ETF Nifty Dividend Opportunities 50
- Nippon India ETF Nifty India Consumption
- Nippon India ETF Nifty Infrastructure BeES
- Nippon India ETF Nifty IT
- Nippon India ETF Nifty PSU Bank BeES
- Nippon India Nifty 50 Value 20 Index Fund
- Nippon India Nifty 500 Equal Weight Index Fund
- Nippon India Nifty 500 Low Volatility 50 Index Fund
- Nippon India Nifty 500 Momentum 50 Index Fund
- Nippon India Nifty 500 Quality 50 Index Fund
- Nippon India Nifty Alpha Low Volatility 30 Index Fund
- Nippon India Nifty Auto ETF
- Nippon India Nifty Auto Index Fund
- Nippon India Nifty Bank Index Fund
- Nippon India Nifty India Manufacturing ETF
- Nippon India Nifty IT Index Fund
- Nippon India Nifty Realty Index Fund
Fund managers from the AMC's filed Scheme Summary — its most recent filing for this scheme. Benchmark and dealing terms from it and this scheme's SEBI-filed Scheme Information Document on AMFI. Each manager's qualifications and role are reconciled across every filing this fund house makes for them, including its Statement of Additional Information. Total AUM via AMFI.
Explore from here
Nippon India in the news
Headlines about the fund house, not this scheme in particular — highlights only; tap through to read the full story at the source.
Nippon Life India AMC sets July 8 AGM, e-voting opens July 4
scanx.trade · 1d ago
Nippon India Ultra Short Term Fund Growth
ClearTax · 4d ago
One in every 3.5 new MF folios came to Nippon India or HDFC in four years
Cafemutual · 6d ago
Nippon India Medium to Long Term Fund - Direct Plan
CNBC TV18 · 6d ago
Nippon India Ultra Short to Short Term Fund - Retail Plan
CNBC TV18 · 6d ago
Nippon India Medium Term Fund - Direct Plan
CNBC TV18 · 6d ago
CARE Ratings to host Nippon India Mutual Fund meet on Sep 30
scanx.trade · 11d ago
HDFC MF sells 1.45% stake in Escorts Kubota for Rs 453 crore; Nippon India MF buys shares
Fortune India · 11d ago
Returns and risk are computed from NAV history and may differ slightly from other portals due to methodology (rolling vs point-to-point, dividend treatment). For research only — not investment advice.
About Index funds & ETFs
Index funds and ETFs must keep at least 95% in the securities of the index they track, rather than trying to beat it. They charge far lower fees than active funds, and their return is the index's return minus that small cost and any tracking difference.
Frequently asked questions
What is the NAV of Nippon India Nifty Pharma ETF?
As of 01 Oct 2026, the NAV of Nippon India Nifty Pharma ETF is ₹27.05 per unit. NAV (net asset value) is the fund's per-unit price, published once each business day.
What returns has Nippon India Nifty Pharma ETF delivered?
Nippon India Nifty Pharma ETF has returned +21.50% over 1 year, +19.93% per year over 3 years, +13.09% per year over 5 years and +12.78% per year since inception. Figures beyond one year are annualised (CAGR) and are computed from AMFI NAV history, so they may differ slightly from other portals.
What is the expense ratio of Nippon India Nifty Pharma ETF?
Nippon India Nifty Pharma ETF charges an expense ratio of 0.23% per year. This annual fee is already deducted from the NAV, so the returns you see are net of it.
What are the top holdings of Nippon India Nifty Pharma ETF?
Nippon India Nifty Pharma ETF's largest holdings are Sun Pharmaceutical Industries Limited (20.8%), Divi's Laboratories Limited (11.9%), Cipla Limited (7.8%), Laurus Labs Limited (7.4%) and Torrent Pharmaceuticals Limited (7.3%). Holdings are disclosed monthly and change over time.
How risky is Nippon India Nifty Pharma ETF?
Nippon India Nifty Pharma ETF is rated very high on SEBI's risk-o-meter, its trailing-3Y volatility (annualised) is 15.1% and its worst peak-to-trough fall in our sample was -21.0%. Higher volatility means the NAV swings more; the drawdown shows how far it has fallen from a peak historically.
What does the Sharpe ratio of 0.89 mean?
The Sharpe ratio is return earned per unit of total risk, above a 6.5% risk-free rate. Nippon India Nifty Pharma ETF's 0.89 means it has rewarded its volatility with excess return. Higher is better.
What is the benchmark of Nippon India Nifty Pharma ETF?
Nippon India Nifty Pharma ETF is benchmarked against the Nifty Pharma TRI. Its alpha and beta on this page are measured against that index.
Who manages Nippon India Nifty Pharma ETF?
Nippon India Nifty Pharma ETF is managed by Jitendra Tolani at Nippon India.
How is Nippon India Nifty Pharma ETF taxed?
Nippon India Nifty Pharma ETF is an equity-oriented fund, so its capital gains get concessional rates: short-term gains (units held under 1 year) are taxed at 20%, and long-term gains (held 1 year or more) at 12.5% above a ₹1.25 lakh per-year exemption. These rates apply on redemption and don't add to your income-tax slab.